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Recent investigations in our laboratory propose that the plasma kallikrein/kinin 
system (KKS) counterbalances the renin-angiotensin system (RAS). The endothelial 
cell prekallikrein activating enzyme, prolylcarboxypeptidase, also degrades 
angiotensin II (ATII). This finding along with the fact that the angiotensin 
converting enzyme (ACE) degrades bradykinin (BK) and forms ATII, plasma 
kallikrein activates prorenin, BK stimulates tPA, NO, and PGI2 liberation whereas 
ATII increases PAI1 and tissue factor levels, and the BKB2 receptor (BKB2R) and 
angiotensin 1 receptor cross talk intracellularly support that assessment. We sought 
animal models to examine the interaction between these two systems. Since C1 
inhibitor knockout (KO) mice have constitutive intravascular kallikrein formation and 
BK elevation, we examined whether the absence of BKB2R influenced the time to 
thrombosis in its KO. BK is the most potent stimulator of tPA liberation in vivo; 
alternatively, the BKB2R accounts for 40% metabolism of BK. The Rose Bengal 
model for carotid artery thrombosis was established.
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